Phenomix Sciences

AI driven precision obesity medicine

health AIprecision medicineobesity/metabolic health

Visit website

StageSeries A2

YC batchNot YC-backed

Raised$14.25M

Founded2021

Employees14

LocationSaint Paul, MN

Business modelB2B, SaaS

About

Phenomix Sciences is a precision medicine obesity biotechnology pioneer on a mission to conquer obesity globally through the science of phenotyping, the understanding of how genes combined with environmental and behavioral factors can inform obesity treatment plans. Mayo Clinic physicians, scientists, and researchers, Drs. Acosta and Camilleri, founded the company under the belief that the key to understanding obesity is unprecedented access to its clinical and molecular information throughout all stages and phenotypes of the disease. Phenomix leverages data intelligence to yield better accuracy in predicting individual patient response to specific weight loss interventions and reducing the variability in weight loss results for patients.

Product

Value proposition: An AI-enabled platform that integrates genetic, clinical, and biomarker data to map biological pathways driving weight gain and treatment response, enabling a scalable shift toward systematic precision obesity care and matching patients to the right intervention at the right time.
Target customers: clinicians, health systems, obesity care programs

Founders

Andres Acosta
Michael Camilleri

Products

MyPhenome TestAI platform for precision medicinePlatform-enabled obesity care solutions

Key features

AI-enabled platform that maps biological pathways driving weight gain and treatment responseintegration of genomic, phenotypic, clinical and biomarker datasetsMyPhenome Test identifies root-cause phenotype and informs therapeutic pathwayspredicts therapeutic pathways and supports scalable outcomes

Technologies

AI/MLgenomicsbiomarker analyticsdata integration

Integrations

EHR systemsclinical data platforms

Target conditions

obesityweight managementmetabolic syndrome

Care settings

hospitalclinicvirtual care

Traction metrics

161+ (context suggests patients or deployments; exact meaning not provided)Projection metrics related to GLP-1 spend (2033)obesity medications (contextual)

Competitors

not provided

Investors

National Institutes of HealthDexComLabcorp Venture FundHealth2047Southeast Minnesota Capital FundMinnesota Department of Employment and Economic Development

News

Phenomix Sciences: Home · 2026-01-11T00:00:00.000Z
Phenomix Sciences Launches MyPhenome® Test Directly to ... · 2026-06-16T00:00:00.000Z
Precision, not hype: Phenomix CEO on the future of obesity treatment · 2025-07-30T08:29:49.000Z
Phenomix Sciences Launches Clinical Trial to Predict GLP-1 Response · 2025-04-08T13:29:00.000Z
New Mayo Clinic Studies Demonstrate MyPhenome Test Predicts Weight Loss Outcomes Across Treatments, Including GLP-1s and Surgical Interventions · 2026-05-05T13:00:00.000Z
Obesity care gets personalised: tailoring therapies with Phenomix · 2025-03-04T00:00:00.000Z

Browse similar startups

Related startups

Pleural Dynamics, Inc. — Wayzata, MN
Pops — Oak Park Heights, MN
Senphonix — Saint Paul, MN
Serenity Behavioral Health & Wellness LLC — Savage, MN
SUGAR LOAF SENIOR LIVING — Winona, MN
Toothapps® — Wayzata, MN
PhyxUp Health — San Francisco, CA
SynchNeuro, Inc. — Chicago, IL
Vena Vitals — irvine, CA
Braveheart Bio — San Francisco, CA
CareAtlas Inc — Austin, TX
Corveus Medical — Houston, TX

Profile updated Jul 29, 2026. Sources: phenomixsciences.com, myphenometest.com